Manufacturing, Marketing And Distribution Agreements Between Biotech Companies: Feb. 17-April 20, 2005

Company*
(Country;
Symbol)

Company*
(Country;
Symbol)

Product

Terms/Details (Date)

Agencourt
Bioscience
Corp.*

Amplicon Express Inc.*

Alliance to co-market a suite of BAC library construction and sequencing services

Each will provide technology to the effort focused on bacteria artificial chromosomes, which are vectors designed to clone DNA fragments (3/21)

Ambion
Diagnostics
(unit of Ambion
Inc.*)

AcroMetrix Corp.*

AcroMetrix will manufacture Armored RNA- based products and distribute them to laboratories and manufacturers

Ambion will supply AcroMetrix custom products based on the Armored RNA technology for further development; terms were not disclosed (3/16)

Auxilium
Pharmaceuticals
Inc. (AUXL)

Oscient Pharmaceuticals Corp. (OSCI)

Two-year deal to co-promote Auxilium's marketed product Testim in the U.S. for treating hypogonadism

Oscient will promote Testim to primary care physicians, and share profits from those sales above a pre-determined base- line (4/13)

BioBalance
Corp. (OTC BB:
BBAL)

Benchmark Biolabs Inc.*

Benchmark will manufacture ProBactrix for clinical trials

The product is a live strain of E. coli M-17 being developed for gastrointestinal disorders; terms were not disclosed (3/14)

Biomedical
Frontiers Inc.*

Hemosol Corp. (Canada; HMSL)

Hemosol will produce the iron-binding drugs 40SD02 and 25SD04 for Biomedical

The injectable drug formulations will be used for preclinical and clinical studies in iron poisoning, iron overload and diabetic complications; terms were not disclosed (4/4)

EDC
Biosystems
Inc.*

Aurora Discovery Inc.*

Deal to co-market EDC's acoustic liquid-handling instrumentation and Aurora's ChemLib microplates

Terms of the deal were not disclosed (3/21)

Halozyme
Therapeutics
Inc. (AMEX:HTI)

Peregrine
Pharmaceuticals
Inc. (PPHM)

Deal for the manufacture of a Halozyme recombinant human enzyme, which will be used in its Cumulase and Enhanze SC producs

The manufacturing will be performed by Peregrine subsidiary Avid Bioservices Inc.; terms of the deal were not disclosed (2/17)

Hawaii Biotech
Inc.*

Cobra Bio- manufacturing plc (UK;LSE:CBF)

Cobra will manufacture materials for clinical trials of vaccines against dengue fever and West Nile disease

Terms of the deal were not disclosed; trials of the recombinant subunit vaccine candidates are expected to begin in 2006 (3/2)

Inyx Inc.
(OTC BB:IYXI)

Kos Pharmaceuticals Inc. (KOSP)

10-year deal under which Inyx will produce Kos' Azmacort Inhalation Aerosol product line

Inyx said the deal is expected to generate about $10M in annual revenues (4/15)

Omnia
Biologics Inc.*

AT-GC BioPharm Inc.*

Deal to develop AT-GC Electronic Eye technology for the manufacture of biopharmaceuticals

They will work together to provide the technology under undisclosed terms (3/24)

Quantum Dot
Corp.*

Chemicon International (subsidiary of Serologicals Corp.; SERO)

Chemicon got rights to market specific quantum dot-containing products for detecting antibody-antigen interactions in immunological experiments

The deal adds secondary antibody detection technologies to Chemicon's general reagents product portfolio; terms were not disclosed (3/4)

Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.